Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Feb 20;13(2):e0191993.
doi: 10.1371/journal.pone.0191993. eCollection 2018.

Rifampicin Versus Streptomycin for Brucellosis Treatment in Humans: A Meta-Analysis of Randomized Controlled Trials

Affiliations
Free PMC article
Meta-Analysis

Rifampicin Versus Streptomycin for Brucellosis Treatment in Humans: A Meta-Analysis of Randomized Controlled Trials

Fanjie Meng et al. PLoS One. .
Free PMC article

Abstract

Brucellosis is a zoonotic disease with a high morbidity in developing countries, but there the optimal treatment is not yet determined. Therefore, the development of a simple and effective treatment is important. The aim of this study was to summarize the available evidences and compare rifampicin with streptomycin in human brucellosis with doxycycline as background regimen. We systematically searched PubMed, EmBase, and the Cochrane Library from their inception up through December 2016. We included studies with a randomized controlled design that evaluated the effect of streptomycin compared with rifampicin in human brucellosis patients who received doxycycline therapy as background regimen. The overall failure and relapse were summarized using random-effects model. Our meta-analysis included 1,383 patients with brucellosis from 14 trials. We found that patients who received rifampicin therapy had a higher risk of overall failure (RR: 2.36; 95% CI: 1.72-3.23; P<0.001) and relapse (RR: 2.74; 95% CI: 1.80-4.19; P<0.001) compared with streptomycin. Results of the sensitivity analysis were consistent with the overall analysis. Subgroup analysis indicated that mean age of the patients and percentage of male participants might influence the treatment effects. Furthermore, no publication bias was detected. The findings of this study indicated that rifampicin therapy significantly increased the risk of overall failure and relapse compared with streptomycin. Hence, it can be recommended to patients with human brucellosis receiving streptomycin therapy.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Study selection process.
Fig 2
Fig 2. Risk of bias graph of included RCTs.
Fig 3
Fig 3. Risk of bias summary of included RCTs.
Fig 4
Fig 4. Effect of rifampicin therapy on the incidence of overall failure.
Fig 5
Fig 5. Effect of rifampicin therapy on the incidence of relapse.
Fig 6
Fig 6. Funnel plots.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Young EJ. An overview of human brucellosis. Clin Infect Dis. 1995; 21: 283–289; quiz 290. - PubMed
    1. Arnow PM, Smaron M, Ormiste V. Brucellosis in a group of travelers to Spain. JAMA. 1984; 251: 505–507. - PubMed
    1. Centers for Disease C, Prevention. Brucellosis outbreak at a pork processing plant—North Carolina, 1992. MMWR Morb Mortal Wkly Rep. 1994; 43: 113–116. - PubMed
    1. Young EJ, Suvannoparrat U. Brucellosis outbreak attributed to ingestion of umpasteurized goat cheese. Arch Intern Med. 1975; 135: 240–243. - PubMed
    1. Saltoglu N, Tasova Y, Inal AS, Seki T, Aksu HS. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J. 2002; 23: 921–924. - PubMed

Publication types

MeSH terms

Grant support

The authors received no specific funding for this work.
Feedback